《Protara Therapeutics, Inc. (TARA) 2025年第一季度财报(10-Q)「NASDAQ」.pdf》由会员分享,可在线阅读,更多相关《Protara Therapeutics, Inc. (TARA) 2025年第一季度财报(10-Q)「NASDAQ」.pdf(44页珍藏版)》请在三个皮匠报告上搜索。
1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549 FORM 10-Q(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31,2025 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE AC
2、T OF 1934 For the transition period from to Commission File Number:001-36694 Protara Therapeutics,Inc.(Exact name of registrant as specified in its charter)Delaware 20-4580525(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)345 Park Avenue South3rd Floor
3、New York,NY(Address of principal executive offices)10010(Zip Code)(646)844-0337(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Trading Symbol(s)Name of each exchange on which registeredCommon Stock,$0.001 par value persh
4、are TARA The Nasdaq Global Market Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the SecuritiesExchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file suchreports),and
5、(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or
6、for such shorter period thatthe registrant was required to submit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smallerreporting company,or an emerging growth company.See the definitions of“large accelerat